Overblog Alle Blogs
Edit post Folge diesem Blog Administration + Create my blog
MENU

Mein Blog umfasst die aktuellesten News, Forschungsleistung, neuesten Produkte und Service von Sino Biological Inc. und die aktuelle News von Life Sciences. Sie können sich hier wissenschaftlich informieren.Willkommen zu meinem Blog.Viel Spaß!

Werbung

CD22 Antikörper

Sino Biological Inc. liefert CD22 Antikörper mit höherer Qualität und günstiger Kosten im Vergleich mit anderen globalen Lieferanten.

Weitere Informationen über CD22 Antikörper lesen Sie bitte: http://www.sinobiological.com/CD22-Antibody-g-10138.html

Produkt-Information von CD22 Antikörper

Immunogen

Recombinant Human CD22 protein (Catalog#11958-H08H)

Antibody Type Mouse Monoclonal Antibody ( Mouse mAb Service Platform )

Clone ID

07

Ig Type

Mouse IgG1

Formulation 0.2 μm filtered solution in PBS with 5% trehalose
Preparation

This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD22 (rh CD22; Catalog#11958-H08H; P20273-1; Met 1-Arg 687). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.

Usage Guide von CD22 Antikörper

Specificity

Human CD22

 

No cross-reactivity in ELISA with

Human cell lysate (293 cell line)

Direct ELISA This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human CD22. The detection limit for Human CD22 is approximately 0.078 ng/well.
Storage This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

Hintergrund von CD22 Antikörper

Related Areas:

Immunology>>Cluster of Differentiation>>B Cell CD Antigen>>CD22

Proteins:
Molecule Species Description //For Detailed Info. and Price------CLICK! Cat. No
CD22 Human CD22 Protein, Recombinant 11958-H08H
Antibodies:
Molecule Application Description //For Detailed Info. and Price------CLICK! Cat. No
Human CD22 FCM CD22 Antibody ( FITC ) 11958-MM05-F
Human CD22 ELISA CD22 Antibody 11958-MM07

Hintergrund von CD22 Antikörper

CD22 is a molecule belonging to the immunoglobulin superfamily, SIGLEC (sialic acid binding Ig-like lectin) family. It is a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. The CD22 cell-surface adhesion molecule is capable of modulating B lymphocyte antigen receptor (BCR)-mediated signals, as well as the generation of BCR-independent signals. CD22 is an inhibitory coreceptor of the B-cell receptor (BCR), and plays a critical role in establishing signalling thresholds for B-cell activation. CD22 recruits the tyrosine phosphatase Src homology 2 domain-containing phosphatase 1 (SHP-1) to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and inhibits B-cell receptor (BCR)-induced Ca2+ signaling on normal B cells. CD22 interacts specifically with ligands carrying alpha2-6-linked sialic acids. Interaction of CD22 to ligands in trans can regulate both B-cell migration as well as the BCR signaling threshold. However, a more complex role for CD22 has recently emerged, including a central role in a novel regulatory loop controlling the CD19/CD21-Src-family protein tyrosine kinase (PTK) amplification pathway that regulates basal signaling thresholds and intensifies Src-family kinase activation after BCR ligation. CD19 regulates CD22 phosphorylation by augmenting Lyn kinase activity, while CD22 inhibits CD19 phosphorylation via SHP-1. Thus, the CD19/CD22 loop may be a potential therapeutic target in autoimmune disease for modulating B cell signaling.

References

  1. Sato S. et al., 1998, Semin Immunol. 10 (4): 287-97.
  2. Walker JA. et al., 2008, Immunology. 123 (3): 314-25.
  3. Nitschke L. 2009, Immunol Rev. 230 (1): 128-43.
  4. Tedder TF. et al., 2005, Adv Immunol. 88: 1-50.
  5. Fujimoto M. et al., 2007, J Dermatol Sci. 46 (1): 1-9.

Primary Antibody Products

Werbung
Zurück zu Home
Diesen Post teilen
Repost0
Um über die neuesten Artikel informiert zu werden, abonnieren:
Kommentiere diesen Post